Enterprise Value
30.02B
Cash
2.371B
Avg Qtr Burn
N/A
Short % of Float
3.57%
Insider Ownership
0.42%
Institutional Own.
92.21%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis | Approved Update | |
OXLUMO® (lumasiran) Details Primary hyperoxaluria | Approved Quarterly sales | |
Leqvio® (inclisiran) Details Transthyretin amyloidosis, Atherosclerotic cardiovascular disease | Approved Quarterly sales | |
ONPATTRO® (Patisiran) Details Transthyretin amyloidosis | Approved Quarterly sales | |
AMVUTTRA (Vutrisiran) Details Transthyretin amyloidosis, Cardiomyopathy | sNDA Submission | |
ONPATTRO® (Patisiran) Details Transthyretin amyloidosis | sNDA FDA meeting | |
FITUSIRAN Details Hemophilia | NDA Submission | |
ALN-TTRsc04 Details Transthyretin amyloidosis | Phase 3 Initiation | |
Elebsiran (ALN-HBV02 [VIR-2218] +/- VIR-3434) Details Hepatitis D, Hepatitis B | Phase 2 Data readout | |
Zilebesiran (ALN-AGT) Details Metabolic disorder, Pulmonary arterial hypertension | Phase 2 Update | |
ALN-HSD Details Non-alcoholic steatohepatitis | Phase 1 Data readout | |
Mivelsiran (ALN-APP) Details Alzheimer's disease, Cerebral Amyloid Angiopathy | Phase 1 Data readout | |
ALN-PNP Details Non-alcoholic steatohepatitis | Phase 1 Update | |
ALN-KHK Details Type 2 diabetes | Phase 1a Data readout | |
ALN-XDH Details Arthritis, Chronic refractory gout | Failed Discontinued | |
OXLUMO® (lumasiran) Details Kidney disease | Failed Discontinued |